Evidence map›Paper›PMID 29995750›Full record

Observational studyMedicine2018

Use of epoprostenol to treat severe pulmonary vasoconstriction induced by protamine in cardiac surgery.

Zheng Guan, Xin Shen, Yong-Jian Zhang, Xiao-Gang Li, Yan-Feng Gao, Jing Tan, Hui Yuan, Jing-Jie Liu

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Zheng GuanDepartment of Anesthesiology, the First Affiliated Hospital Department of Cardiac Surgery, the First Affiliated Hospital Department of Neurology, the Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
Xin Shen
Yong-Jian Zhang
Xiao-Gang Li
Yan-Feng Gao
Jing Tan
Hui Yuan
Jing-Jie Liu
First Affiliated Hospital of Chinese PLA General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since there were a few articles to report the treatment of severe pulmonary vasoconstriction induced by protamine in cardiac surgery, we described the use of epoprostenol to reverse this condition.A total of 5 cases of severe pulmonary vasoconstriction induced by protamine in cardiac surgery were reviewed. The demographic, clinical data and treatment process were obtained. All the patients were followed up.Severe pulmonary vasoconstriction was occurred 4 to 10 minutes after protamine infusion. The primary sign was sudden hypotension, the pulmonary artery pressure was increased gradually, the arterial oxygen partial pressure was decreased in all the patients. Epoprostenol was infused via pulmonary artery catheter at dosage of 20 to 40 ng/kg·min in all the patients, 2 patients were underwent re-cardiac pulmonary bypass assistance. The hemodynamic instability status lasted 40 to 65 minutes respectively. All the patients were recovered uneventfully.All physicians should alert to the incidence of severe pulmonary vasoconstriction induced by protamine in cardiac surgery. Use epoprostenol through pulmonary artery catheter could treat pulmonary artery vasoconstriction effectively and safely.

Indexed as

Hypertension, PulmonaryIntraoperative ComplicationsAdultAgedAntihypertensive AgentsCardiac Surgical ProceduresChinaDrug MonitoringEpoprostenolFemaleHemodynamicsHeparin AntagonistsHumansMaleMiddle AgedMonitoring, IntraoperativeAntihypertensive AgentsEpoprostenolHeparin AntagonistsProtamines

Identifiers

PMID29995750
PMCPMC6076185
OpenAlexW2859966785

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.